About: Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $61.63 (-1.85%)
CYTK NASDAQ Cytokinetics Inc
Cytokinetics Inc share price
CYTK price activity
Last Price
$61.630
Change (24hr)
-1.16 USD (-1.85%)
Volume
1.45M
Volume (4w avg)
-
Open
$62.32
Day Range
$61.63 - $62.32
Previous Close
$62.79
Last Trade
13 Oct, 7:58 pm GMT+0
Delayed
13 Oct, 7:58 pm GMT+0
CYTK price performance
Delayed
13 Oct, 7:58 pm GMT+0
CYTK Market Signals